BR112015006363A2 - combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r - Google Patents

combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r

Info

Publication number
BR112015006363A2
BR112015006363A2 BR112015006363A BR112015006363A BR112015006363A2 BR 112015006363 A2 BR112015006363 A2 BR 112015006363A2 BR 112015006363 A BR112015006363 A BR 112015006363A BR 112015006363 A BR112015006363 A BR 112015006363A BR 112015006363 A2 BR112015006363 A2 BR 112015006363A2
Authority
BR
Brazil
Prior art keywords
vegf
agents
pharmaceutical combinations
binders
angiopoietin
Prior art date
Application number
BR112015006363A
Other languages
English (en)
Inventor
Gschwind Andreas
Baum Anke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963602&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015006363(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112015006363A2 publication Critical patent/BR112015006363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo "combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r" a presente invenção se refere a combinações farmacêuticas que compreendem ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r para uso no tratamento de doenças como câncer e doenças oculares. são ainda descritos ligantes anti-ang2/anti-dll4 duplos para uso no tratamento de câncer em combinação com agentes anti-vegf-r, e composições farmacêuticas compreendendo as combinações farmacêuticas da invenção.
BR112015006363A 2012-09-28 2013-09-26 combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r BR112015006363A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12186695 2012-09-28
PCT/EP2013/070143 WO2014049099A1 (en) 2012-09-28 2013-09-26 Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents

Publications (1)

Publication Number Publication Date
BR112015006363A2 true BR112015006363A2 (pt) 2017-08-08

Family

ID=46963602

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006363A BR112015006363A2 (pt) 2012-09-28 2013-09-26 combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r

Country Status (17)

Country Link
US (1) US20140093498A1 (pt)
EP (1) EP2900261A1 (pt)
JP (1) JP2015532272A (pt)
KR (1) KR20150060687A (pt)
CN (1) CN104661678A (pt)
AR (1) AR092736A1 (pt)
AU (1) AU2013322640A1 (pt)
BR (1) BR112015006363A2 (pt)
CA (1) CA2883807A1 (pt)
CL (1) CL2015000761A1 (pt)
EA (1) EA201500370A1 (pt)
IL (1) IL237645A0 (pt)
MX (1) MX2015003895A (pt)
PH (1) PH12015500663A1 (pt)
TW (1) TW201427688A (pt)
UY (1) UY35054A (pt)
WO (1) WO2014049099A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514866A (ja) * 2014-05-06 2017-06-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｂｒａｆ阻害剤を使用する創傷治癒
CA2963606A1 (en) * 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
BR112017009817A2 (pt) 2014-11-10 2018-02-14 Hoffmann La Roche anticorpos anti-il-1beta e métodos de utilização
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
ES2877712T3 (es) 2015-02-02 2021-11-17 Mei Pharma Inc Terapias combinadas para su uso en el tratamiento del cáncer de mama
CA3061053A1 (en) * 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070671A2 (en) 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
EP2032604A2 (en) * 2006-06-06 2009-03-11 Genentech, Inc. Anti-dll4 antibodies and methods using same
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
CA2726267C (en) 2008-06-06 2017-10-31 Boehringer Ingelheim International Gmbh Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US8192738B2 (en) * 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2459191A1 (en) * 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2

Also Published As

Publication number Publication date
EP2900261A1 (en) 2015-08-05
US20140093498A1 (en) 2014-04-03
AU2013322640A1 (en) 2015-03-12
IL237645A0 (en) 2015-04-30
TW201427688A (zh) 2014-07-16
CL2015000761A1 (es) 2015-08-07
KR20150060687A (ko) 2015-06-03
PH12015500663A1 (en) 2015-05-18
AR092736A1 (es) 2015-04-29
CA2883807A1 (en) 2014-04-03
MX2015003895A (es) 2015-07-17
WO2014049099A1 (en) 2014-04-03
JP2015532272A (ja) 2015-11-09
EA201500370A1 (ru) 2015-08-31
CN104661678A (zh) 2015-05-27
UY35054A (es) 2014-04-30

Similar Documents

Publication Publication Date Title
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
GB201209613D0 (en) New compounds
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112014026703A2 (pt) inibidores de dna-pk
PH12015500664A1 (en) Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
UA118018C2 (uk) Ациламінопіримідинові похідні для лікування вірусних інфекцій та інших захворювань
BR112015003751A2 (pt) conjugados da anticorpo-droga (adc) que se ligam a proteínas 158p1d7
BR112015004875A2 (pt) formulações de anticorpo e seus usos
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112014027047A2 (pt) nova formulação
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]